34.15

0.41% +0.14

Inhibrx Inc (INBX)

Overview News Price History Option Chain Financials Discussions Forecast

Inhibrx Inc stock is currently priced at $34.15, with a 24-hour trading volume of 244.86K. It has seen a +0.41% increased in the last 24 hours and a -2.65% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $34.12 pivot point. If it approaches the $34.33 resistance level, significant changes may occur.

Previous Close:

$34.01

Open:

$34.35

24h Volume:

244.86K

Market Cap:

$1.62B

Revenue:

$1.80M

Net Income/Loss:

$-241.36M

P/E Ratio:

-8.4321

EPS:

-4.05

Net Cash Flow:

$-197.90M

1W Performance:

+0.26%

1M Performance:

-2.65%

6M Performance:

+87.43%

1Y Performance:

+26.53%

1D Range:

$33.87

$34.45

52W Range:

$14.30

$39.79

Inhibrx Inc Stock (INBX) Company Profile

Name

Inhibrx Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

858-795-4220

Address

11025 North Torrey Pines Road, Suite 200, La Jolla

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

INBX's Discussions on Twitter

Inhibrx Inc Stock (INBX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Mar-16-22	Initiated	SMBC Nikko	Outperform
Sep-21-21	Initiated	JMP Securities	Mkt Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Sep-14-20	Initiated	Credit Suisse	Outperform
Sep-14-20	Initiated	Evercore ISI	Outperform

View All

Inhibrx Inc Stock (INBX) Latest News

Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More

Zacks Investment Research

Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?

Zacks Investment Research

Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi

Zacks Investment Research

Inhibrx Inc Stock (INBX) Financials Data

Inhibrx Inc (INBX) Revenue 2024

INBX reported a revenue (TTM) of $1.80 million for the quarter ending December 31, 2023, a -17.36% decline year-over-year.

Inhibrx Inc (INBX) Net Income 2024

INBX net income (TTM) was -$241.36 million for the quarter ending December 31, 2023, a -66.20% decrease year-over-year.

Inhibrx Inc (INBX) Cash Flow 2024

INBX recorded a free cash flow (TTM) of -$197.90 million for the quarter ending December 31, 2023, a -70.62% decrease year-over-year.

Inhibrx Inc (INBX) Earnings per Share 2024

INBX earnings per share (TTM) was -$5.12 for the quarter ending December 31, 2023, a -41.44% decline year-over-year.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.